JATT II Acquisition Corp. JATT
10.25 USD 0.00 (-0.03%)
Nov 3, 2026, 12:12 PM EST
10.25 Day range 10.25
9.99 52-week range 23.76
- YTD
- -2.38%
- 1 year
- -2.38%
- Market cap
- 79.97M
- Shares out
- 1.69M
- YTD return
- -2.38%
- 1-year return
- -2.38%
- Volume
- 47
- Avg volume
- 20.63K
- Open
- 10.32
- Previous close
- 10.25
- Day's range
- 10.25 – 10.25
- 52-week range
- 9.99 – 23.76
1Y -0.25 (-2.38%)
Key statistics
- Enterprise value
- 140.99M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 74.45K
- Total debt
- 299.98K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 10.29
- 200-day average
- 10.12
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
JATT Revenue — quarterly 0
JATT Net income — quarterly -305.55K
JATT EPS — quarterly -0.05
About JATT II Acquisition Corp.
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- Cayman Islands
- Website
- jattacquisition.com
News
JATT Acquisition (NYSE:JATT) Stock Price Down 2.1% – Here’s Why 
JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering 
JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering 
JATT II Acquisition To Merge With Talawar Therapeutics; Combined Company Expects To Receive $285M In PIPE Financing Upon Closing 
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases 
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering 
JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering 
JATT Acquisition Corp Announces Planned Transfer Of Listing To NASDAQ In Connection With Its Proposed Business Combination With Zura Bio Limited 
With The Execution Of The License Agreement, For Lilly Entering Into The License Agreement With Z33, JATT And Lilly Entered Into That Certain Equity Grant Agreement, Pursuant To Which JATT Agreed To Issue And Grant To Lilly 550K Class A Ordinary Shares In A Private Placement Transaction - On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company
Your note
Sign in to keep a note on JATT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Hudson Bay Capital Management Lp | 7.58% | 1,306,750 | 10.66M | Dec 30, 2022 |
| Magnetar Financial LLC | 6.69% | 1,153,700 | 9.41M | Dec 30, 2022 |
| Glazer Capital LLC | 5.80% | 999,980 | 8.16M | Dec 30, 2022 |
| Marshall Wace LLP | 2.82% | 486,402 | 3.97M | Dec 30, 2022 |
| Shaolin Capital Management LLC | 2.61% | 450,000 | 3.67M | Dec 30, 2022 |
| Boussard & Gavaudan Investment Management LLP | 2.17% | 375,000 | 3.06M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Merger Fund, The | 1.39% | 240,325 | 1.96M | Sep 29, 2022 |
| Investment Managers Ser Tr II-First Trust Merger Arbitrage Fd | 0.69% | 118,750 | 969.00K | Sep 29, 2022 |
| JNL Series Trust-JNL/Multi Manager Alternative Fund | 0.06% | 10,708 | 87.38K | Sep 29, 2022 |
| Merger Fund Vl, The | 0.02% | 3,011 | 24.57K | Sep 29, 2022 |